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Abstract 	
Purpose: Teenage and young adult (TYA) cancer survivors experience a range of health-
related problems during and beyond the active treatment period. This study examined 
associations between fatigue, sleep quality, and health-related quality of life (HR-QoL) 
among TYA survivors. 
Methods: Self-reported data on sleep quality (Pittsburgh Sleep Quality Index), fatigue 
(Functional Assessment of Chronic Illness Therapy Fatigue) and HR-QoL (EuroQoL-5) were 
gathered from UK TYA survivors aged between 13 and 24 years. TYA survivors were 
stratified into those on (n=67) and off (n=135) treatment. Linear regression analyses were 
used with HR-QoL as the dependent variable to investigate potential associations. Fatigue and 
sleep were entered separately, and together in the same model. Age at survey and diagnosis, 
gender and ethnicity were included as covariates. 
Results: 85.07% of TYAs on and 62.69% of TYAs off treatment had sleep quality scores 
suggestive of clinically significant sleep disorders. 56.72% of TYAs on and 26.67% of 
TYAsoff treatment reported clinically significant levels of fatigue. Strong independent 
associations between sleep (B=0.05, 95% CI=0.03-0.07, p<0.001), fatigue (B=0.02, 95% 
CI=0.01-0.03, p<0.001), and HR-QoL were observed among TYA survivors on treatment. 
TYAs off treatment showed moderate to strong associations between sleep (B=0.04, 95% 
CI=0.02-0.05, p<0.001) and fatigue (B=0.02, 95% CI=0.01-0.02, p<0.001), and HR-QoL, 
when examined separately. Sleep was not independently associated with HR-QoL among 
TYAs off treatment (B=0.01, 95% CI=-0.01-0.02, p=0.296). 
Conclusion: The significant associations reported suggest sleep quality and fatigue are 
potential modifiable factors associated with HR-QoL. Further research is warranted to 
understand the direction of associations. 
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Introduction 
Each day seven young people aged between 13 and 24 years (TYA) are diagnosed with 
cancer in the United Kingdom (UK).1 Advances in cancer therapies mean the five-year 
survival rate among TYAs is now >80%.2 However, TYA survivors suffer significant 
impairments in health-related quality of life (HR-QoL) throughout and after treatment3,4 
including psychosocial and physical limitations experienced up to ten years after treatment.5 
Identifying potential modifiable factors associated with on and off treatment HR-QoL in TYA 
survivors is important as targeting these in interventions may in the long-term improve 
outcomes in this population. 
 
More recently, there has been increasing interest in fatigue.6 Fatigue is defined as ‘‘a 
subjective, unpleasant symptom, which incorporates total body feelings ranging from 
tiredness to exhaustion creating an unrelenting overall condition which interferes with 
individuals’ ability to function to their normal capacity’.7 Fatigue experienced by cancer 
survivors i.e. cancer-related fatigue (CRF), is often of greater magnitude, disproportionate to 
activity levels, and cannot be resolved through resting.8 CRF may be caused by tumor-related 
productions of cytokines, pain and neuroendocrine factors, and by medication and 
treatment.9,10 A review of mainly quantitative observational cross-sectional and longitudinal 
studies suggests CRF is the most prevalent symptom of TYA cancer treatment,6with more 
than 75% of cancer patients reporting the condition.11  Across 22 studies included in the 
review, CRF was found to often result in distress, and to impact on TYA survivors’ cognitive 
and physical function.6  However, findings are limited in strength, as the studies conducted 
were of relatively low quality,6 and often evaluated fatigue mainly as a sub component of 
more general measures, such as the Memorial Symptom Assessment Scale Short Form 
(MSAS-SF).12 Nevertheless cross-sectional studies involving survivors of childhood cancer 
and adult cancer survivors provide evidence for assocations between CRF and HR-QoL. 
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Fatigue was found to be associated with poorer physical and psychosocial functioning in 86 
survivors (age range= 8-18 years) of childhood cancer on average 7.8 years after treatment,13 
and with poorer HR-QoL in 954 adult cancer patients with mixed cancer diagnoses.14 
 
While interest in investigating fatigue among TYA survivors has been increasing, there has 
been less emphasis on sleep quality. In general, engagement in poor sleep hygiene behaviors 
means many young people suffer from sleep problems.15 Among TYA survivors poor sleep 
may be associated both with increased fatigue and impaired HR-QoL. Sleep problems in 
cancer survivors may arise as a direct effect of the cancer, and be caused by indirect effects, 
including aspects of poor HR-QoL such as pain and anxiety.16 Within one small longitudinal 
study of 20 TYAs receiving chemotherapy (mean age=16.12 years) significant associations 
were found between poor sleep quality and poor cancer-related quality of life, including 
cognitive problems, pain and anxiety.17 Another study found significant associations between 
poor sleep and impaired HR-QoL in a sample of 61 TYA survivors (age range= 12-25 years) 
who had finished all treatment (r=-0.57, p>0.001).18 Poor sleep quality was also correlated 
with bodily pain and impaired vitality, in a sample of 72 adult breast cancer survivors.19 
Additionally, poor sleep in TYA survivors often occurs simultaneously with fatigue,20 and the 
adult literature suggests a reciprocal relationship.12 
 
Given that adolescence and young adulthood are characterised by unique psychosocial 
developmental changes, including increasing independence and transitions in school and work 
settings, good HR-QoL is important. Thus, it is essential to explore potential modifiable 
factors associated with poor HR-QoL in TYA survivors. Fatigue and poor sleep quality are 
suggested as such factors. However, findings that indicate associations within the TYA 
survivor population are limited in reliability, as studies suggesting an association between 
fatigue and HR-QoL have mainly been of low quality6 and studies investigating sleep quality 
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used predominantly small samples sizes.17 Furthermore, TYA survivors are a unique group in 
terms of tumor type and prognosis.21 While the majority of TYA survivors receive their 
cancer diagnosis during adolescence or young adulthood, survivors of childhood cancer will 
have been diagnosed during childhood. Evidencecoming from this group, or adult cancer 
survivors can thus not be directly extrapolated to TYA-aged survivors. Using distinct and 
detailed measures the aim of this study was therefore to examine associations between sleep 
quality, fatigue, and HR-QoL in a large sample of TYA survivors. It was hypothesised that 
there are associations between sleep quality, fatigue, and HR-QoL in the TYA survivor 
population. 
 
Methods 
Study design, procedure, and participants 
In 2015-2016 TYA survivors were recruited to participate in a cross-sectional survey study 
investigating their health behaviors, well-being and interest in lifestyle advice.  Detailed 
information regarding the recruitment procedure can be found in a previous publication.22 
TYA survivors were eligible if they had a diagnosis of cancer at any point within their 
lifetime; have had, have, or were going to receive active treatment for their cancer; were aged 
between 13 and 24 years; were living in the UK during the time of data collection; and 
understood spoken and written English. TYAs with terminal cancer, receiving palliative care 
or unable to provide consent themselves were excluded from the study. Interested participants 
were given an information sheet outlining the purpose of the study. All eligible TYAs could 
consent themselves independent of their age; interested young people were assumed to have 
Gillick competence.23 Participants who agreed to participate were offered either a paper-
version of the survey, or a link where it could be completed online. After finishing the 
questionnaire participants could fill in their personal details to be included in a prize draw to 
win vouchers worth £15-£50. Ethical approval was obtained from UCL Research Ethics 
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Committee (project number: 6206/001) and London Hampstead NHS Research Ethics 
Committee (reference: 15/LO/0764). 
 
Measures 
Demographic information and health characteristics 
Self-reported data on age, gender and ethnicity were collected alongside self-reported data on 
health characteristics including cancer type, cancer stage, treatment type, treatment stage and 
age at diagnosis. Since chemotherapy and radiotherapy are known to have a negative impact 
on sleep and fatigue20, TYA survivors were classified as having received/receiving 
chemotherapy and/or radiotherapy or having received/receiving neither of the two. 
Additionally, information on health problems other than the primary cancer was gathered. 
Participants were asked to indicate whether they have had any health problems in addition to 
their primary cancer, including osteoporosis, diabetes, asthma, irregular heart rhythm, 
extreme fatigue, mental health problems, lung disease, arthritis, any other heart trouble, 
another cancer, sensory impairments or specified other problems. Responses were categorized 
into ‘no health problem present’ and ’health problem present’ (≥ one additional health 
problem present). 
 
Fatigue 
Fatigue was measured as the total score of the 13-item fatigue subscale of the Functional 
Assessment of Chronic Illness Therapy Fatigue (FACIT-F) questionnaire. On a five-point 
Likert scale, the questionnaire assesses the intensity of fatigue and its impact on daily life 
over the past seven days.16 Examples of items included in the scale are “I feel fatigued”, “I 
feel tired” and “I have to limit my social activity because I am tired”. After reverse scoring 
items seven (“I have energy“) and eight (“I am able to do my usual activities”), a global score 
ranging from zero to 52 is obtained. Higher scores indicate greater levels of fatigue. The 
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FACIT-F is widely accepted as a measure of fatigue in cancer patients,24 with high internal 
validity (Cronbach’s α=0.96)25 and good test-retest reliability (r=0.90)25. Scores above 22 are 
considered as clinically significant fatigue.26 
 
Sleep 
Sleep quality over the past month was measured using the Pittsburgh Sleep Quality Index 
(PSQI). The 19-question scale has seven dimensions: subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication and 
daytime dysfunction. The individual dimensions can be evaluated separately, or combined to 
give a global score ranging from zero to 21, with greater scores indicating poorer sleep 
quality. The PSQI was validated for cancer patients (Cronbach’s α=0.81),27 and shows good 
reliability (r=0.85).27 The cut-off score is set at five, to identify cases with clinical sleep 
disorders.28 
 
HR-QoL 
HR-QoL was measured with the EuroQoL-5, a valid (Cronbach’s α=0.71) and reliable (r>0.7) 
measure of health status that is widely used in cancer research.29 The five-item questionnaire 
assesses mobility, self-care, daily activities, discomfort/pain, and anxiety/depression at the 
day of survey on a five-point Likert scale.29 Individual dimension scores are added to give a 
global score ranging from five to 25. Higher scores indicate poorer HR-QoL. 
 
Statistical analyses 
Participants who started the survey but did not complete any items contained within either the 
HR-QoL, sleep or fatigue measures were excluded from all analyses. Where participants 
completed outcome measures partially, missing data were imputed using expectation 
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maximization algorithm.30 Data were not imputed for any demographic variables or health 
characteristics, and pairwise deletion was applied to minimize loss of data.31 
 
Descriptive statistics were calculated for all variables. Following the advice of the TYA 
clinical team and after testing for an interaction by treatment status (B=0.01, β=0.62, 95% 
CI=0.01-0.02, p<0.001 for treatment status * fatigue interaction; B=0.03, β=0.46, 95% 
CI=0.02-0.04, p<0.001 for treatment status * sleep interaction) TYA survivors were stratified 
into those on and off treatment. In the UK a TYA survivor is defined as any young person 
between the ages of 13 and 24 years living with or beyond cancer.32 Both groups are 
consequently widely referred to as TYA survivors,33 yet they differ in their needs.34 TYAs 
undergoing treatment struggle with hospitalization and treatment-related side effects such as 
nausea, whilst TYA survivors off treatment are faced with challenges regaining a sense of 
normalcy to their lives.  TYAs who reported undergoing active treatment at survey were 
classified as TYA survivors on treatment. TYAs who reported not having started treatment or 
to have finished all active treatment were categorized as TYA survivors off treatment. 
 
Prior to main analyses associations between sleep and fatigue were explored. HR-QoL was 
log transformed to account for the non-normality of data. Simple linear regressions were run 
to test for unadjusted associations between sleep and HR-QoL, and fatigue and HR-QoL with 
HR-QoL as the dependent variable. Then models adjusting for covariates were run, with 
demographics and age at diagnosis entered as covariates, and sleep or fatigue as variables of 
main interest. Separateregressions were run for sleep and fatigue. To investigate whether 
sleep and fatigue were independently associated with HR-QoL additional analyses were 
carried out that included sleep and fatigue in the same model. TYA survivors on and off 
treatment commonly reported to suffer from extreme fatigue and mental health problems such 
as anxiety, in addition to their cancer. To avoid overlap with the measures included in this 
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study the presence of an additional health problem was not adjusted for. Other cancer-specific 
health characteristics such as cancer type were not controlled for, as no significant 
associations between these and any of the key variables were found in preliminary analyses. 
 
All data were analysed using IBM SPSS Version 24.0. The significance level was set at α= 
0.05 for all analyses. 95% confidence intervals (95% CI), and standardized regression 
coefficients (β) as effect size estimates, were reported (with β<0.2=small, 
0.2<β<0.5=medium, β>0.5=strong).35 Due to a lack of effect sizes reported in studies 
suggesting an association between fatigue and HR-QoL among TYA cancer survivors sample 
size calculations for the present study were based on a recent quantitative study which found a 
large significant correlation (r=-0.57) between sleep quality and HR-QoL among TYA 
survivors in the first year post treatment.18 Power calculations suggested samples of minimum 
55 participants were required to observe associations (linear regressions, large effect size, 
power of 80%, α=0.05). 
 
Results 
Response rate 
In total, 295 eligible TYA survivors began the survey, 85 of whom did not complete any 
items contained within either HR-QoL, sleep or fatigue measures. They were thus excluded 
from analyses. Sixty-seven TYAs reported to currently receive active cancer treatment, and 
135 TYAs said to be off treatment. The remaining eight survivors did not indicate their 
treatment status.  
 
Sample and health characteristics 
Table 1 and Table 2 provide an overview of the demographic information of the study 
population, and their health characteristics, respectively. The average age at survey for TYA 
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survivors on treatment was 19.57 years (SD=3.14), and 20.17 years (SD=2.86) for survivors 
off treatment. The majority of participants were female (64.18% for on treatment, 65.19% for 
off treatment) and White (85.07% for on treatment, 86.67% for off treatment). 
 
TYA survivors on treatment (mean age=17.80 years, SD=3.25) were significantly older at 
diagnosis compared to survivors off treatment (mean age=16.27 years, SD=4.31) (p=0.015). 
The majority of TYAs on (67.16%) and off treatment (60.74%) reported the presence of an 
additional health problem. The two groups differed in cancer type (p=0.015). Almost all 
TYAs on (95.52%) and off treatment (94.81%) reported to have received/receive 
chemotherapy and/or radiotherapy as cancer treatment. Most survivors on (47.76%) and off 
treatment (40.74%) were unsure about the stage of cancer they had been diagnosed with. The 
majority of TYAs off treatment (45.19%) had finished their treatment between one and five 
years prior to survey. 
 
Table 3 lists the mean scores for sleep, fatigue and HR-QoL. 85.07% of TYAs on treatment 
and 62.96% of TYAs off treatment had PSQI sleep quality scores above five, suggesting 
possible clinically significant sleep disorders.28 56.72% of TYAs on and 26.67% of TYAs off 
treatment had fatigue scores indicating clinically significant levels of fatigue.(3)  Sleep 
quality and fatigue were significantly associated among TYA survivors on (β=0.41, 95% 
CI=0.54-1.98,B=1.26, p=0.001) and off treatment (β=0.54, 95% CI=1.21-2.17, B=1.69, 
p<0.001). 
 
Associations with HR-QoL 
Table 4 presents results of regression analyses among TYA survivors on treatment. In 
separate adjusted analyses sleep quality (β=0.49, 95% CI=0.03-0.07, B=0.05, p<0.001) and 
fatigue (β=0.55, 95% CI=0.01-0.03, B=0.02, p<0.001) were strongly associated with HR-
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QoL. When entering sleep quality and fatigue into the same model both variables showed 
strong independent associations with HR-QoL (β=0.32, 95% CI=0.01-0.06, B=0.03, p=0.009 
for sleep quality, β=0.41, 95% CI=0.01-0.02, B=0.01, p=0.002 for fatigue). 
 
Table 5 lists results of analyses including TYA survivors off treatment. Moderate to strong 
associations were found between sleep quality and HR-QoL (β=0.43 95% CI=0.02-0.05, 
B=0.04, p<0.001), and fatigue and HR-QoL (β=0.67, 95% CI=0.01-0.02, B=0.02, p<0.001). 
After entering sleep quality and fatigue into the same model fatigue was strongly associated 
with HR-QoL (β=0.63, 95% CI=0.01-0.02, B=0.02, p<0.001) but no association was found 
between sleep quality and HR-QoL (β=0.08, 95% CI=-0.01-0.02, B=0.01, p=0.296). 
 
Discussion 
A cross-sectional survey design was used to test for associations between fatigue, sleep 
quality, and HR-QoL among TYA survivors. High prevalence of clinical sleep problems and 
fatigue were observed across the sample. After stratification by treatment status moderate to 
strong associations were observed between sleep quality, fatigue and HR-QoL among TYA 
survivors on and off treatment. While fatigue was found to be independently associated with 
HR-QoL in both groups independent associations between sleep quality and HR-QoL were 
found in TYA survivors on treatment, but not among survivors off treatment. 
 
The high prevalence of sleep problems and fatigue observed among TYA survivors is in line 
with past research that found sleep onset latency suggestive of insomnia in 41% of TYA 
survivors in their first year post treatment.18 Another study found increased fatigue among 
TYA survivors on treatment compared to general population TYAs.3 While poor sleep quality 
is common also among TYAs from the general population36 the high percentage found in this 
study is particularly concerning as sleep disruption can cause circadian rhythm dysregulation 
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which is linked to poor health outcomes including poorer cancer prognosis.37,38 Additionally, 
fatigue hinders the development of adolescent key needs, including autonomy and close peer 
relationships.39 
 
  
 
The significant associations found between fatigue and HR-QoL in TYAs on and off 
treatment are supported by findings of a review that suggests fatigue in TYA survivors was 
associated with increased levels of distress and reduced mobility.6 Using the MSAS, which 
allows comparisons of the level of distress caused by each symptom, fatigue was found in the 
top half in the majority of studies included in the review. Another review of mainly 
qualitative studies described the impact of fatigue on children and adolescents with cancer as 
an increased need to sleep and rest, and therefore to not being able to take part in regular 
activities.40 
 
The finding that sleep quality was strongly associated with HR-QoL among TYA survivors is 
in line with past research involving TYA and adult cancer survivors. Associations between 
increased sleep-wake disturbances and impaired cancer-related quality of life were observed 
in a small sample of TYAs receiving chemotherapy.17 Another study found associations 
between poor sleep quality and impaired HR-QoL among TYA survivors in the first year post 
treatment. Moreover, diminished sleep quality was associated with impaired cognitive 
functioning and poorer functional status in 115 adult lung cancer patients undergoing 
chemotherapy.41 
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Strong associations were found between sleep quality and fatigue both in TYA survivors on 
and off treatment. However, sleep quality among those on treatment is likely to be 
additionally impacted by treatment-specific factors such as hospitalization.9 This may explain 
why sleep was found to be associated with HR-QoL independent of fatigue in TYA survivors 
on treatment but not among those off treatment. 
 
Several limitations need to be addressed when interpreting the findings of this study. First, as 
this study is a cross-sectional design, assumptions about causal relationships between sleep, 
fatigue and HR-QoL cannot be made. Second, the study used self-report measures, thus 
introducing potential biases including over- or underestimation of certain outcomes such as 
sleep duration.42 Inclusion of objective tools, such as actigraphy43 would have been valuable. 
Third, to reduce the burden related to study participation it was decided to include the 
EuroQoL-5 as a brief measure of HR-QoL, yet a more detailed measure may have yielded in 
more insightful findings. Fourth, this study used a UK sample of TYA survivors aged 
between 13 and 24 years. Findings are therefore limited in generalizability to TYAs from 
countries that apply different age ranges to define TYA survivors.44 Despite aforementioned 
limitations, the present study had important strengths. Although a large number of TYA 
survivors, particularly those on treatment, appears to suffer from sleep disorders, and our 
findings suggest poor sleep quality to be strongly associated with impaired HR-QoL in this 
group, only one study has to date investigated sleep quality among TYA survivors.18 
Additionally, this study included exclusively TYA survivors in the first year after having 
finished treatment.18 The present study is thus the first sufficiently powered quantitative study 
to examine associations between sleep quality and HR-QoL, and to describe the prevalence of 
sleep disorders among TYA survivors on treatment. Moreover, previous studies that 
examined associations between fatigue and HR-QoL6 evaluated fatigue mainly as a sub 
component of more general measures.12 The present study in contrast used a distinct and 
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detailed measure of fatigue.25 Furthermore, it was the first study to investigate whether sleep 
quality and fatigue are independently associated with HR-QoL among TYA survivors on and 
off treatment. 
 
Future research should aim to identify the direction of associations between sleep quality, 
fatigue and HR-QoL. Equally, longitudinal repeated-measures study should identify the 
underlying mechanisms of poor sleep and HR-QoL, and fatigue in TYA survivors on and off 
treatment. Once the direction of associations has been clarified studies including large 
numbers of participants per cancer and treatment type are required to investigate potential 
cancer/treatment- and demographic-related differences among TYA survivors to identify 
those who are in greatest need of potential interventions.    
 
The present study suggests potentially high prevalence of sleep disorders and fatigue, and has 
identified probable associations between sleep and fatigue, and HR-QoL among TYA 
survivors. Poor sleep quality and fatigue are suggested as potential modifiable factors 
associated with poor HR-QoL among TYA survivors on and off treatment. Targeting sleep 
and fatigue in tailored interventions may therefore improve on and off treatment HR-
QoLoutcomes. Furthermore, the finding that sleep quality was independently associated with 
HR-QoL among TYA survivors on treatment but not among those off treatment suggests that 
interventions TYA survivors on and off treatment may benefit from different interventions. 
However, the causes of poor sleep and HR-QoL, and fatigue among TYA survivors are 
complex and yet to be understood. Large-scale longitudinal studies using subjective and 
objective measures are needed to understand the exact mechanisms underlying fatigue, and 
poor sleep and HR-QoL before starting the development of potential interventions. 
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